Introduction
A number of in-vitro model systems have been introduced for the study of the action of morphine-like drugs. Their usefulness depends on their relative simplicity, compared to the brain and central nervous system, and on the good correlation observed between potencies in the models and potencies in the whole animal. For example, the contractions of the isolated gui nea\x=req-\ pig ileum and mouse vas deferens to electrical stimulation at low frequencies are inhibited by opiate analgesics due to a reduced release of the motor transmitters acetylcholine (Paton, 1957) and noradrenaline (Henderson, Hughes & Kosterlitz, 1972) respectively, and the order of potencies in these smooth muscle models correlates well with the analgesic potencies of these drugs (see Kosterlitz & Waterfield, 1975) .
Observations with these and other model systems lead to the belief that the site of action of opiates included a specific receptor in the true, pharmacological sense; but it seemed unlikely to many workers in the field of opiate research that such apparently selective receptors should have been developed by Nature to interact with the opium alkaloids. Accordingly, the idea that the opiate receptors must be receptors for "an endogenous humoral substance" was proposed by Collier (1972) .
Experimental support for this hypothesis came shortly afterwards when Akil, Mayer & Liebskind (1972) reported that analgesia could be produced in rats by electrical stimulation through electrodes implanted in the periaqueductal region of the brain and that this "stimulationevoked analgesia" was reduced by administering the morphine antagonist drug naloxone. These results were taken to mean that the brain contained an endogenous substance which produced a morphine-like analgesic effect by interacting with the opiate receptor and which could be released by electrical stimulation. It was then that concerted efforts commenced in several centres to isolate the endogenous morphine-like substance.
The discovery of the endogenous opioid peptides
The first attempts to isolate the endogenous ligand for the opiate receptor had been unsuccessful due to the mistaken presumption of chemical similarity to morphine, but in 1975 Hughes reported the isolation from aqueous extracts of brain of a material, 'enkephalin', which was peptide in nature and produced morphine-like responses in the in-vitro model systems. This extract of enkephalin was later shown to contain a mixture of two pentapeptides whose structures were H-Tyr-Gly-Gly-Phe-Met-OH (methionine-enkephalin) and H-Tyr-Gly-Gly-PheLeu-OH (leucine-enkephalin) . Hughes et al. recognized that the amino acid LPH61_9l), which itself was present in the pituitary, had the methionine-enkephalin sequence at its N-terminus and also had morphine-like activity (Bradbury, Smyth, Snell, Birdsall & Hulme, 1976; Lazarus, Ling & Guillemin, 1976; Li & Chung, 1976) . Other fragments, including aendorphin (ß-LPH61_76) and -endorphin (ß-LPH61_77), have also been isolated from the pituitary and have opioid activity (Guillemin, Ling & Burgus, 1976; Lazarus et al, 1976) , although recent evidence suggests that these may be artefacts of extraction or breakdown products of ß-endorphin, as C-fragment is now known (Rossier et al, 1977a) .
It was originally proposed that methionine-enkephalin might be derived from ß-endorphin which in turn was derived from ß-LPH and by analogy that similar precursors might exist for leucine-enkephalin . Attractive as this hypo¬ thesis may be, there is no experimental evidence in its favour (see . Although ß-endorphin in the pituitary may be derived from ß-LPH (Chrétien et al, 1978) , the enkephalins in both central and peripheral sites are synthesized locally from as yet unknown precursors .
The distributions of the endogenous opioid peptides have been determined by several different techniques and the results suggest that the enkephalins and ß-endorphin form two independent systems.
Enkephalins are widely distributed, both in the brain and the periphery. They are particularly concentrated in the corpus striatum and hypothalamus of guinea-pig brain and the myenteric plexus of guinea-pig small intestine. Although the ratio of the contents of methionine-and leucine-enkephalin varies from region to region, methionine-enkephalin is always present in a greater concentration (Hughes, Kosterlitz & Smith, 1977) . Immunohistochemical studies have shown enkephalin-like immunoreactive material in laminae I and II of the spinal cord, the sub¬ stantia gelatinosa of the spinal trigemminal nucleus, the vagai nuclei, the periventricular and periaqueductal areas of the upper medulla and midbrain, the dorso-medial thalamus, the globus pallidus and the central nucleus of the amygdala (Eide, Hökfelt, Johansson & Terenius, 1976; Hökfelt, Eide, Johansson, Terenius & Stein, 1977; Hökfelt, Ljungdahl, Eide, Nilsson & Terenius, 1977; Simantov, Kuhar, Uhi & Snyder, 1977) . This immunofluorescence is mainly associated with nerve fibres and terminals which suggests that the enkephalins may be neurotransmitters.
ß-Endorphin is more restricted in its distribution with high concentrations in the anterior and intermediate lobes of the pituitary and lower concentrations in a few brain areas around the midline and in the hypothalamus, thalamus, midbrain and pons (Cox, Goldstein & Li, 1976; Bloom et al, 1977; Rossier et al, 1977c; Bloom, Battenberg, Rossier, Ling & Guillemin, 1978) .
Physiological significance of the opioid peptides
When the existence of the enkephalins and ß-endorphin was firmly established, many researchers were interested to examine whether these peptides produced morphine-like analgesia in the standard tests for anti-nociception in animals. The natural enkephalins had only a small and transient effect, even after intracerebroventricular injection (see Pert, Bowie, Fong & Chang, 1976) while ß-endorphin showed a strong and long-lasting anti-nociceptive action (Feldberg & Smyth, 1976; Loh, Tseng, Wei & Li, 1976; Pert, 1976; . In the mouse tail-flick test, ß-endorphin was 48 times more potent that morphine, on a molar basis, after intra¬ cerebroventricular injection and 3-4 times more potent after intravenous injection (Li, 1977 (Taube, Borowski, Endo & Starke, 1976) and acetylcholine (Subramanian et al, 1977) from rat brain and of substance from rat trigemminal nucleus (Jessel & Iversen, 1977) . This role may also extend to the periphery since the stimulationinduced release of acetylcholine from the guinea-pig ileum and of noradrenaline from the mouse vas deferens is reduced by enkephalin (Waterfield, Smokcum, Hughes, Kosterlitz & Henderson, 1977) . The presence of ß-endorphin-like immunoreactive material in the midline pathway in the brain (Bloom et al, 1978) suggests that this peptide may have a similar, if somewhat less wide¬ spread, control function. The role of ß-endorphin in the pituitary has been the subject of more intense speculation.
ß-Endorphin may itself be a pituitary hormone. Either ß-endorphin or its putative precursor ß-LPH is stored within secretory granules (Queen, Pinsky & La Bella, 1976; La Bella, Queen & Senyshyn, 1977) and plasma levels of ß-endorphin increase in parallel with those of adrenocorticotrophin (ACTH) during stressful procedures in animals (Rossier et al, 1977b; . Whether the release of ß-endorphin and ACTH is generally controlled by similar mechanisms is not yet known, but it seems likely that their biosyntheses are closely associated. Recent evidence suggests that they share a common, high molecular weight precursor, "proopiocortin" (Mains, Eipper & Ling, 1977; Roberts & Herbert, 1977a, b; Rubinstein, Stein & Udenfriend, 1978) . Also, pituitary levels of both increase after adrenalectomy and both increases are reduced by dexamethasone .
Alternatively, or in addition, ß-endorphin within the pituitary may play some role in the control of hypophysial hormone release or synthesis. This may be a direct action since opiate receptors are present in the pituitary (Simantov & Snyder, 1977) , or may be exerted at the hypo¬ thalamic level since the possibility of retrograde transport of hypophysial hormones in the vasculature of the pituitary stalk has recently been demonstrated (Oliver, Mical & Porter, 1977; Bergland & Page, 1978 Bisset, Chowdrey & Feldberg (1978) have observed an antidiuretic effect with leucineenkephalin, D-Ala2 D-Leu'-enkephalin and ß-endorphin in water-loaded rats similar to that first described with morphine in the dog (de Bodo, 1944) . These authors showed that the response to leucine-enkephalin was reduced by naloxone and that for the stable enkephalin analogue at least, the antidiuresis was accompanied by an increased excretion of vasopressin-like material in the urine. Weitzman, Fisher, Minick, Ling & Guillemin (1977) found increased levels of arginine vasopressin in the blood of rabbits after intravenous injection of ß-endorphin, but van Wimersma Greidanus et al (1979) have claimed that in both normal and water-deprived rats morphine and ß-endorphin produce decreases in plasma levels of arginine vasopressin with a corresponding increase in a-melanocyte stimulating hormone. Weitzman et al (1977) Shaar, Frederickson, Dininger & Jackson, 1977) . There is one report of release of prolactin from cultured pituitary cells by enkephalin (Lien, Fenichel, Garsky, Sarantakis & Grant, 1976 ) but more recent evidence contradicts this and suggests that the release of both GH and prolactin by morphine and opioid peptides is not due to a direct action on the pituitary (Rivier et al, 1977; Shaar et al, 1977) . Grandison & Guidotti (1977) and Guidotti & Grandison (1978) concluded that endogenous opioids control the release of prolactin by inhibiting dopaminergic mechanisms in the mediobasal hypo¬ thalamus. Their evidence for this is: (1) that naltrexone administration reduces the serum levels of prolactin in intact rats and in rats with deafferentation of the hypothalamus; (2) that dopamine, but not naltrexone, reduces release of prolactin from pituitary halves in vitro; (3) that intrahypothalamic injection of naltrexone reduces, and of ß-endorphin increases, serum prolactin levels; (4) that after dopamine receptor blockade by haloperidol or depletion of dopamine stores by reserpine, serum prolactin levels are increased and that these elevated levels are undiminished by naltrexone. The observation that administration of an opiate antagonist alone reduces the serum concentration of prolactin has been confirmed by other groups who also showed that GH was similarly affected (Bruni, van Vugt, Marshall & Meites, 1977; Shaar et al, 1977) . This is the most convincing evidence for a physiological role of endogenous opioid peptides in the tonic control of the release of GH and prolactin.
Similar evidence suggests that the release of luteinizing hormone (LH) may be under some form of control by enkephalins or ß-endorphin in the mature male rat (Bruni et al, 1977; Blank, Panerai & Friesen, 1979) . In the female rat naloxone administration produces an increase in serum LH at various stages before puberty but not in the adult. Significantly, oestradiol admini¬ stration abolishes the naloxone-induced increase in the prepubertal female (Blank et al, 1979) .
The results with follicle-stimulating hormone (FSH) are less clear. Morphine has been shown to block the preovulatory surge of FSH as well as of LH in the rat (Pang, Zimmerman & Sawyer, 1977) but Bruni et al. (1977) have reported that although naloxone does increase serum FSH levels in the male rat, morphine does not produce any significant decrease. Conversely, while morphine and methionine-enkephalin decreased levels of thyroid stimulating hormone, an action blocked by naloxone, naloxone alone did not increase serum levels of this hormone.
In conclusion, the possibility that opioid peptides are involved in the control of pituitary hormone release must now be considered in spite of the comparative paucity of well controlled and systematic studies. The 
